Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.

People & HR

Operations

New York, NY, USA

Boston, MA, USA

Elevation Oncology

Vertex Ventures HC

Discover opportunities across our network of portfolio companies.

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Vertexventureshc Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Vertexventureshc network as they come up.

You can always update this information later.

Welcome to the Vertexventureshc talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Vertexventureshc company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Your professional information is now visible to our team and companies in our network.
We will be in touch when we find a great opportunity for you at one of our companies.

Thanks for signing up

As our companies grow, they look to us to help them find the best talent.
Signal that you'd be interested in working with a Vertexventureshc company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Portfolio Careers